{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:11:32Z","timestamp":1785172292549,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40265-021-01558-2","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T11:02:21Z","timestamp":1626951741000},"page":"1331-1342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Netupitant\/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting"],"prefix":"10.1007","volume":"81","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"issue":"14 Suppl","key":"1558_CR1","first-page":"S259","volume":"23","author":"N Adel","year":"2017","unstructured":"Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017;23(14 Suppl):S259\u201365.","journal-title":"Am J Manag Care."},{"issue":"1","key":"1558_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"25","author":"J Herrstedt","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, et al. 2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25(1):277\u201388.","journal-title":"Support Care Cancer"},{"issue":"24","key":"1558_CR3","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782\u201397.","journal-title":"J Clin Oncol"},{"key":"1558_CR4","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guildelines in Oncology (NCCN Guidelines\u00ae): antiemesis (version 1.2021). 2020. https:\/\/www.nccn.org. Accessed 24 May 2021."},{"issue":"1","key":"1558_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00520-016-3365-1","volume":"25","author":"F Roila","year":"2017","unstructured":"Roila F, Warr D, Hesketh PJ, et al. 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer. 2017;25(1):289\u201394.","journal-title":"Support Care Cancer"},{"key":"1558_CR6","unstructured":"US FDA. Akynzeo\u00ae (netupitant and palonosetron capsules; fosnetupitant and palonosetron for injection; fosnetupitant and palonosetron injection): US prescribing information. 2020. https:\/\/www.fda.gov. Accessed 24 May 2021."},{"key":"1558_CR7","unstructured":"European Medicines Agency. Akynzeo: summary of product characteristics 2021. https:\/\/www.ema.europa.eu. Accessed 24 May 2021."},{"issue":"18","key":"1558_CR8","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s40265-015-0512-9","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM. Netupitant\/palonosetron: a review in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2015;75(18):2131\u201341.","journal-title":"Drugs."},{"key":"1558_CR9","unstructured":"European Medicines Agency. Akynzeo: EPAR\u2014public assessment report. 2015. https:\/\/www.ema.europa.eu. Accessed 24 May 2021."},{"issue":"4","key":"1558_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/j.1476-5381.1995.tb13282.x","volume":"114","author":"EH Wong","year":"1995","unstructured":"Wong EH, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 1995;114(4):851\u20139.","journal-title":"Br J Pharmacol"},{"issue":"16","key":"1558_CR11","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.2165\/11200980-000000000-00000","volume":"69","author":"LP Yang","year":"2009","unstructured":"Yang LP, Scott LJ. Palonosetron: in the prevention of nausea and vomiting. Drugs. 2009;69(16):2257\u201378.","journal-title":"Drugs."},{"issue":"2","key":"1558_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1213\/ane.0b013e318172fa74","volume":"107","author":"C Rojas","year":"2008","unstructured":"Rojas C, Stathis M, Thomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 2008;107(2):469\u201378.","journal-title":"Anesth Analg"},{"issue":"2","key":"1558_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1124\/jpet.110.166181","volume":"335","author":"C Rojas","year":"2010","unstructured":"Rojas C, Li Y, Zhang J, et al. The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 2010;335(2):362\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20133","key":"1558_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2012.05.037","volume":"689","author":"M Stathis","year":"2012","unstructured":"Stathis M, Pietra C, Rojas C, et al. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012;689(1\u20133):25\u201330.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"1558_CR15","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s00221-014-4017-7","volume":"232","author":"AG Thomas","year":"2014","unstructured":"Thomas AG, Stathis M, Rojas C, et al. Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014;232(8):2637\u201344.","journal-title":"Exp Brain Res"},{"issue":"2\u20133","key":"1558_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejphar.2009.10.002","volume":"626","author":"C Rojas","year":"2010","unstructured":"Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010;626(2\u20133):193\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"1558_CR17","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdy169","volume":"29","author":"L Schwartzberg","year":"2018","unstructured":"Schwartzberg L, Roeland E, Andric Z, et al. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018;29(7):1535\u201340.","journal-title":"Ann Oncol"},{"issue":"5","key":"1558_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cpdd.192","volume":"4","author":"S Calcagnile","year":"2015","unstructured":"Calcagnile S, Lanzarotti C, Gutacker M, et al. Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: a randomized, open-label, crossover phase 1 study. Clin Pharmacol Drug Dev. 2015;4(5):377\u201386.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"10","key":"1558_CR19","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00520-013-1857-9","volume":"21","author":"S Calcagnile","year":"2013","unstructured":"Calcagnile S, Lanzarotti C, Rossi G, et al. Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013;21(10):2879\u201387.","journal-title":"Support Care Cancer"},{"issue":"7","key":"1558_CR20","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","volume":"25","author":"PJ Hesketh","year":"2014","unstructured":"Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7):1340\u20136.","journal-title":"Ann Oncol"},{"issue":"4","key":"1558_CR21","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00520-016-3502-x","volume":"25","author":"M Aapro","year":"2017","unstructured":"Aapro M, Karthaus M, Schwartzberg L, et al. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer. 2017;25(4):1127\u201335.","journal-title":"Support Care Cancer"},{"issue":"7","key":"1558_CR22","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","volume":"25","author":"M Aapro","year":"2014","unstructured":"Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25(7):1328\u201333.","journal-title":"Ann Oncol"},{"issue":"7","key":"1558_CR23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","volume":"25","author":"RJ Gralla","year":"2014","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25(7):1333\u20139.","journal-title":"Ann Oncol"},{"issue":"2","key":"1558_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"L Zhang","year":"2018","unstructured":"Zhang L, Lu S, Feng J, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018;29(2):452\u20138.","journal-title":"Ann Oncol"},{"issue":"3","key":"1558_CR25","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1634\/theoncologist.2019-0527","volume":"25","author":"L Schwartzberg","year":"2020","unstructured":"Schwartzberg L, Navari R, Clark-Snow R, et al. Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy. Oncologist. 2020;25(3):e589\u201397.","journal-title":"Oncologist."},{"issue":"5","key":"1558_CR26","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/cam4.2091","volume":"8","author":"L Schwartzberg","year":"2019","unstructured":"Schwartzberg L, Karthaus M, Rossi G, et al. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: efficacy data from 2 randomized, double-blind phase III studies. Cancer Med. 2019;8(5):2064\u201373.","journal-title":"Cancer Med"},{"issue":"14","key":"1558_CR27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2217\/fon-2020-0187","volume":"16","author":"M Karthaus","year":"2020","unstructured":"Karthaus M, Oskay-\u00d6zcelik G, W\u00fclfing P, et al. Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life. Future Oncol. 2020;16(14):939\u201353.","journal-title":"Future Oncol."},{"key":"1558_CR28","unstructured":"European Medicines Agency. Akynzeo: EPAR\u2014assessment report variation. 2020. https:\/\/www.ema.europa.eu. Accessed 24 May 2021."},{"key":"1558_CR29","unstructured":"US FDA. Akynzeo (fosnetupitant and palonosetron) for injection, for intravenous use: multidiscipline review. 2017. https:\/\/www.fda.gov. Accessed 24 May 2021."},{"key":"1558_CR30","unstructured":"US FDA. Palonosetron hydrochloride injection, for intravenous use: US prescribing information. 2016. https:\/\/www.fda.gov. Accessed 24 May 2021."},{"key":"1558_CR31","unstructured":"European Medicines Agency. Aloxi: summary of product characteristics. 2018. https:\/\/www.ema.europa.eu. Accessed 24 May 2021."},{"issue":"31 Suppl 1","key":"1558_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2017.35.31_suppl.227","volume":"35","author":"M Karthaus","year":"2017","unstructured":"Karthaus M, Szab\u00f2 P, Voisin D, et al. Phase III study of palonosetron (PALO) given as 30-min IV infusion (IV inf) versus 30-sec IV bolus (IV bol) for prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy (HEC). J Clin Oncol. 2017;35(31 Suppl 1):227.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1558_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1634\/theoncologist.2015-0301","volume":"21","author":"M Aapro","year":"2016","unstructured":"Aapro M, Hesketh PJ, Jordan K, et al. Safety of an oral fixed combination of netupitant and palonosetron (NEPA): pooled data from the phase II\/III clinical program. Oncologist. 2016;21(4):494\u2013502.","journal-title":"Oncologist."},{"issue":"389","key":"1558_CR34","first-page":"1","volume":"3","author":"T Spinelli","year":"2014","unstructured":"Spinelli T, Moresino C, Baumann S, et al. Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial. Springerplus. 2014;3(389):1\u201311.","journal-title":"Springerplus."},{"key":"1558_CR35","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0023","author":"RM Navari","year":"2021","unstructured":"Navari RM, Binder G, Bonizzoni E, et al. Single-dose netupitant\/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021. https:\/\/doi.org\/10.2217\/fon-2021-0023.","journal-title":"Future Oncol."},{"key":"1558_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.breast.2017.02.017","volume":"33","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Rossi G, Rizzi G, et al. Efficacy of NEPA (netupitant\/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: a subanalysis from two phase III trials. Breast. 2017;33:76\u201382.","journal-title":"Breast"},{"issue":"4","key":"1558_CR37","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00520-017-3936-9","volume":"26","author":"PJ Hesketh","year":"2018","unstructured":"Hesketh PJ, Palmas M, Nicolas P. Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic. Support Care Cancer. 2018;26(4):1151\u20139.","journal-title":"Support Care Cancer"},{"issue":"6","key":"1558_CR38","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1097\/IGC.0000000000001292","volume":"28","author":"SM Bo\u0161njak","year":"2018","unstructured":"Bo\u0161njak SM, Stamatovic L, Borroni ME, et al. Efficacy and safety of oral NEPA (netupitant\/palonosetron), the first fixed-combination antiemetic, in patients with gynecological cancers receiving platinum-based chemotherapy. Int J Gynecol Cancer. 2018;28(6):1153\u201361.","journal-title":"Int J Gynecol Cancer."},{"issue":"1","key":"1558_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jgo.2016.09.002","volume":"8","author":"M Aapro","year":"2017","unstructured":"Aapro M, Jordan K, Gralla RJ, et al. Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients. J Geriatr Oncol. 2017;8(1):56\u201363.","journal-title":"J Geriatr Oncol."},{"key":"1558_CR40","unstructured":"US FDA. Emend (fosaprepitant for injection): US prescribing information. 2019. https:\/\/www.fda.gov. Accessed 24 May 2021."},{"issue":"4","key":"1558_CR41","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/jcph.1338","volume":"59","author":"J Gilmore","year":"2019","unstructured":"Gilmore J, Bernareggi A. Complementary pharmacokinetic profiles of netupitant and palonosetron support the rationale for their oral fixed combination for the prevention of chemotherapy-induced nausea and vomiting. J Clin Pharmacol. 2019;59(4):472\u201387.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1558_CR42","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00520-019-04824-y","volume":"28","author":"M Botteman","year":"2020","unstructured":"Botteman M, Nickel K, Corman S, et al. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR\u2009+\u2009GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Support Care Cancer. 2020;28(2):857\u201366.","journal-title":"Support Care Cancer"},{"key":"1558_CR43","doi-asserted-by":"crossref","unstructured":"Bourhis F, Eriksson J, Ruffo P, et al. NEPA, an oral fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting (CINV) in Germany and Greece [abstract no. PCN174]. Value Health. 2018;21(Suppl 3):S43\u20134.","DOI":"10.1016\/j.jval.2018.09.257"},{"key":"1558_CR44","doi-asserted-by":"crossref","unstructured":"Lim SW, Loh KWJ, Boisseau S, et al. Netupitant and palonosetron (NEPA), is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting (CINV) in Singapore [abstract no. PCN206]. Value Health. 2019;22(Suppl 3):S475\u20136.","DOI":"10.1016\/j.jval.2019.09.402"},{"issue":"8","key":"1558_CR45","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1080\/13696998.2019.1620244","volume":"22","author":"SH Park","year":"2019","unstructured":"Park SH, Binder G, Corman S, et al. Budget impact of netupitant\/palonosetron for the prevention of chemotherapy-induced nausea and vomiting. J Med Econ. 2019;22(8):840\u20137.","journal-title":"J Med Econ."},{"issue":"e015645","key":"1558_CR46","first-page":"1","volume":"7","author":"U Restelli","year":"2017","unstructured":"Restelli U, Saibene G, Nardulli P, et al. Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open. 2017;7(e015645):1\u20139.","journal-title":"BMJ Open"},{"key":"1558_CR47","doi-asserted-by":"crossref","unstructured":"Rubio Ponce R, D\u00edaz O, Sinta Cortes G, et al. Economic evaluation of palonosetron\/netupitant for the treatment of chemotherapy-related nausea and vomiting [abstract no. PCN54]. Value Health. 2019;22(Suppl 2):S66.","DOI":"10.1016\/j.jval.2019.04.178"}],"updated-by":[{"DOI":"10.1007\/s40265-021-01607-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01558-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01558-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01558-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T16:02:18Z","timestamp":1635264138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01558-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01558-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"15 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01607-w","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01607-w","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}